Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 3/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22993590 | 0.83 | MAOA (0.38) | MAOAMAOBCYP1A2CYP2D6SLC6A4 | |
| SCHEMBL22993218 | 0.75 | MAOA (0.47) | MAOAMAOBSLC6A4CHRNA7 | |
| SCHEMBL24253490 | 0.74 | HRH3 (0.45) | MAOAMAOBSLC6A4 | |
| SCHEMBL22993447 | 0.74 | MAOA (0.41) | MAOAMAOBCYP1A2CYP2D6SLC6A4 | |
| SCHEMBL25444508 | 0.74 | MAOA (0.50) | MAOAMAOBSLC6A4CHRNA7 | |
| SCHEMBL24253500 | 0.72 | MAOA (0.45) | MAOAMAOBCYP2D6SLC6A4CHRNA7 | |
| SCHEMBL22993619 | 0.71 | MAOA (0.35) | MAOAMAOBSLC6A4HTR6CHRNA7 | |
| SCHEMBL25121131 | 0.70 | DRD2 (0.42) | MAOAMAOBCYP1A2CYP2D6SLC6A4 | |
| SCHEMBL25091105 | 0.69 | HTR2C (0.40) | MAOAMAOBHTR6CHRNA7 | |
| SCHEMBL24253339 | 0.68 | MAOA (0.37) | MAOAMAOBSLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | MAOA 175/4885MAOB 71/4885CYP1A2 876/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | MAOA 175/4885MAOB 71/4885CYP1A2 876/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | MAOA 175/4885MAOB 71/4885CYP1A2 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.